A photo of Scott Raskin.

Scott I. Raskin, DO


  • Pediatric Neuro-Oncologist, Division of Oncology
  • Assistant Professor, UC Department of Pediatrics

About

Biography

As a pediatric neuro-oncologist, my philosophy is to treat my patients' diseases to the best of my ability and care for them and their families as people, not just a condition to cure. Making sure we are here for families and patients as a whole ensures we’re providing the best possible care.

Initially, I was inspired to become a pediatrician because of my childhood pediatrician's care and experience. As I continued through medical training, I was amazed by children's resiliency and knew I wanted to care for them.

I was drawn to pediatric oncology because it uses the most current advances in healthcare. I also enjoy working with the most remarkable patients and families. Their strength inspires me to work harder every day.

In my research, I am trying to better understand how we can cure pediatric central nervous system (CNS) tumors with poor outcomes. I’m also looking at how to treat relapsed or refractory disease using novel clinical trials or therapies and directly translating this research from the lab.

In my free time, I like to explore parks and spend time outside with my family.

Locations (2)

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Raskin, S; Van Pelt, S; Toner, K; Balakrishnan, PB; Dave, H; Bollard, CM; Yvon, E. Molecular Therapy - Methods and Clinical Development. 2021; 23:296-306.

Selected

Considerations when treating high-grade pediatric glioma patients with immunotherapy. Crotty, E; Downey, K; Ferrerosa, L; Flores, C; Hegde, B; Raskin, S; Hwang, E; Vitanza, N; Okada, H. Expert Review of Neurotherapeutics. 2021; 21:205-219.

Selected

Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Li, S; Amat, D; Peng, Z; Vanni, S; Raskin, S; De Angulo, G; Othman, AM; Graham, RM; Leblanc, RM. Nanoscale. 2016; 8:16662-16669.

Subgroup and subtype-specific outcomes in adult medulloblastoma. Coltin, H; Sundaresan, L; Smith, KS; Skowron, P; Massimi, L; Eberhart, CG; Schreck, KC; Gupta, N; Weiss, WA; Tirapelli, D; et al. Acta Neuropathologica. 2021; 142:859-871.

Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. Raskin, S; Bornhorst, M. Otolaryngologic Clinics of North America. 2021; 54:789-801.

Biological and Molecular Markers in the Diagnosis of Childhood Malignancies. Raskin, S; Angiolillo, AL. In: Wong E; Dietzen D; Bennett M; Haymond S, Ed. Biochemical and Molecular Basis of Pediatric Disease. San Diego CA: Academic Press; 2021.

PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies. Zapata, CP; Cuglievan, B; Zapata, CM; Olavarrieta, R; Raskin, S; Desai, K; De Angulo, G. Pediatric Blood and Cancer. 2018; 65.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey